MedPath

Oropharyngeal Administration of Colostrum

Not Applicable
Completed
Conditions
Health Behavior
Interventions
Other: Oropharyngeal administration of sterile water (placebo)
Biological: Oropharyngeal administration of own mother's colostrum
Biological: Oropharyngeal administration of donor human milk
Registration Number
NCT02912585
Lead Sponsor
Federal University of Uberlandia
Brief Summary

Infections are the main causes of morbidity and mortality in very low birth weight infants. Use of mother's own breast milk in feeding these babies is associated with a decreased risk of acquiring nosocomial infection. This protective effect is assigned to a plurality of immune components in human milk. However, clinical instability of the preterm newborn in the first days of life results in delayed initiation of enteral nutrition. Thus, alternative methods for colostrum administration have been investigated, such as oropharyngeal administration with evidence that would be safe and feasible to perform in children admitted to the NICU in the first hours of life. Objective: To evaluate the immune stimulatory effect of oropharyngeal administration of colostrum in the incidence of sepsis in very low birth weight preterm infants.

Detailed Description

Background: Infections are the main causes of morbidity and mortality in very low birth weight infants. Use of mother's own breast milk in feeding these babies is associated with a decreased risk of acquiring nosocomial infection. This protective effect is assigned to a plurality of immune components in human milk. However, clinical instability of the preterm newborn in the first days of life results in delayed initiation of enteral nutrition. Thus, alternative methods for colostrum administration have been investigated, such as oropharyngeal administration with evidence that would be safe and feasible to perform in children admitted to the NICU in the first hours of life.

Objective: To evaluate the immune stimulatory effect of oropharyngeal administration of colostrum in the incidence of sepsis in very low birth weight preterm infants.

Methods: This was a prospective, randomized and blind study that included infants less than 34 weeks gestational age and birth weight less than 1,500 g, from 15 July 2013 to 15 July 2015.

The babies were divided initially into two groups for oropharyngeal administration or not of mother's own milk: Group 1 - underwent oropharyngeal administration of mother's own milk of and Group 2 - underwent oropharyngeal administration of sterile water, considered an inert substance. Newborns who were drawn to the Group 1 and it was not possible to obtain sufficient mother's own milk volume constituted a third group called Group 3 that receive oropharyngeal administration of donor breast milk. Oropharyngeal administration were initiated within the first 48-72 hours of life and maintained for 48 hours. Before the oropharyngeal administration, 24 hours after and 14 days after, samples of blood and urine were collected from the newborns to IgA and lactoferrin dosage.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
145
Inclusion Criteria
  • Birth weight < 1500 g and gestational age < 34 weeks
Exclusion Criteria
  • congenital anomalies
  • gastrointestinal disorders
  • maternal history of substance abuse or positive maternal HIV status.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboOropharyngeal administration of sterile water (placebo)Oropharyngeal administration of sterile water.
Own mother's colostrumOropharyngeal administration of own mother's colostrumOropharyngeal administration of own mother's colostrum.
Donor human milkOropharyngeal administration of donor human milkOropharyngeal administration of donor human milk.
Primary Outcome Measures
NameTimeMethod
Incidence of late-onset sepsisan average of 3 months

Number of participants with late-onset sepsis

Measurement of immunologic factors in urine and blood samples using enzyme-linked immunoassay (ELISA).an average of 3 months

ELISA Index of immunologic factors in urine and blood samples

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath